ENERGY 3 연구: ENPP1 결핍 아동을 대상으로 한 INZ-701의 효능 및 안전성 평가
ENERGY 3 연구: 엑토뉴클레오티드 피로포스파타제/포스포디에스테라제 1(ENPP1) 결핍증이 있는 어린이를 대상으로 INZ-701의 효능과 안전성을 평가하기 위한 무작위 대조 공개 라벨 제3상 연구
The primary purpose of Study INZ701-106 (The ENERGY 3 Study) is to assess the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
INZ-701 is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzyme replacement therapy (ERT) in development for the treatment of ENPP1 Deficiency, an ultra-rare genetic disorder with an incidence of 1 in 64,000 pregnancies.
Study INZ701-106 (The ENERGY 3 Study) is a multi-center, randomized in a 2:1 ratio, controlled, open-label Phase 3 study to evaluate the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.
The study will consist of a Screening Period of up to 52 days (including a washout period of up to 7 days for prohibited medications post-Randomization) and a Randomized Treatment Period (INZ-701 or control) of 52 weeks, followed by an Open-label Extension Period during which all study participants may receive INZ-701, and an End of Study (EOS) Safety visit 30 days after the last dose of INZ-701.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 3단계
연락처 및 위치
연구 장소
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- Ann & Robert H. Lurie Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- The Children's Hospital of Philadelphia
-
-
Texas
-
Fort Worth, Texas, 미국, 76104
- Cook Children's Medical Center
-
-
-
-
-
Riyadh, 사우디 아라비아, 12713
- King Faisal Specialist Hospital and Research Centre
-
-
-
-
-
Dubai, 아랍 에미리트, 30726
- Al Jalila Children's Specialty Hospital
-
-
-
-
-
Manchester, 영국, M13 9WL
- Royal Manchester Children's Hospital
-
-
-
-
-
Montreal, 캐나다, H3T 1C5
- Centre Hospitalier Universitaire (CHU) Sainte-Justine
-
-
-
-
-
Istanbul, 터키 (Türkiye), 34764
- Umraniye Training and Research Hospital
-
Sarıçam, 터키 (Türkiye), 01330
- Cukurova Universitesi Tip Fakultesi
-
-
-
-
-
Le Kremlin-Bicêtre, 프랑스, 94270
- Hôpital Bicêtre, Service d'endocrinologie et diabète de l'enfant (Childhood Endocrinology and Diabetes Department)
-
-
-
-
-
South Brisbane, 호주, 4101
- Queensland Children's Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria
Study participants must meet all of the following inclusion criteria:
- Caregiver's written informed consent after the nature of the study has been explained, and prior to any research-related procedures, per International Conference on Harmonisation (ICH) Good Clinical Practice (GCP)
- Study participant's assent in accordance with local regulations
- A confirmed postnatal molecular genetic diagnosis of ENPP1 Deficiency with biallelic mutations (ie, homozygous or compound heterozygous) performed by a College of American Pathologists/Clinical Laboratory Improvement Amendments (CAP/CLIA) certified laboratory or regional equivalent
- Males and females ≥1 year and <13 years of age at Study Day 1
- Open growth plates of the distal femur and proximal tibia in both legs
- Plasma PPi concentration of <1400 nM at Screening
- 25(OH)D levels of ≥12 ng/mL at Screening
- Radiographic evidence of skeletal abnormalities based on an RSS ≥2
- Women of childbearing potential (WOCBP, as defined in Clinical Trials Coordination Group [CTCG 2024]) must have a negative serum pregnancy test at Screening and must not be breastfeeding
- Males who are sexually active must agree to use condoms from the period following first dose of INZ-701 through 30 days after the last dose of INZ-701
- WOCBP and partners of fertile males who are WOCBP must be using or must agree to use a highly effective form of (as per CTCG) from at least 1 month before the first dose of INZ-701 through 30 days after the last dose of INZ-701 (greater than 5 half-lives of INZ-701)
- In the opinion of the Investigator, able to complete all aspects of the study
Exclusion Criteria
Study participants meeting any of the following exclusion criteria will not be eligible to participate in the study:
- In the opinion of the Investigator, has clinically significant disease or laboratory abnormality not associated with ENPP1 Deficiency that will preclude study participation and/or may confound the interpretation of study results
- If receiving any of the following prohibited medications as indicated in the protocol: systemic corticosteroids (>5 mg prednisone equivalent per day), anti-FGF23 and oral and/or IV bisphosphonates
- Unable or unwilling to discontinue calcitriol or other active forms of vitamin D3 (or analogs) within 7 days prior to Study Day 1 and/or oral phosphate supplements within 36 hours prior to Study Day 1 if randomized to the INZ-701 arm
- Planned orthopedic surgery or other procedures that may confound the interpretation of study results during the 52-week RTP
- Known intolerance to INZ-701 or any of its excipients
- A positive COVID-19 test within 5 days prior to Randomization, only if required as per local regulations or institutional policy
- Previous treatment with INZ-701
- Concurrent participation in another interventional clinical study and/or has received an investigational drug within 5 half-lives of the last dose or within 4 weeks prior to the first dose of INZ-701, whichever is longer, or use of an investigational device
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: INZ-701
Subjects randomized to the INZ-701 arm will be administered a 2.4 mg/kg once weekly dose by subcutaneous (SC) injection for the duration of the 52-week Randomized Treatment Period (RTP). RTP will be followed by a Low-dose Open-label Extension Period during which all study participants will receive INZ-701 at a dose of 2.4 mg/kg QW while the primary analysis is pending. If dose escalation criteria are met, all participants will transition to the Randomized Extension Period (REP) where participants who were originally randomized to INZ-701 during RTP will transition to a higher dose regimen of INZ-701 at 1.8 mg/kg twice weekly. Participants who were originally randomized to the active control arm during RTP will continue receiving INZ-701 at 2.4 mg/kg QW in the REP. |
Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
다른 이름들:
|
|
활성 비교기: Control Arm (Conventional Therapy)
Subjects randomized to the control arm will continue taking their conventional therapy as clinically indicated by their treating physician for the duration of the 52-week Randomized Treatment Period. |
Conventional therapy is defined as oral phosphate supplements and calcitriol or other active forms of vitamin D3 (or analogs). No other agents for treatment of ENPP1 Deficiency are allowed in the control arm. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from Baseline in Plasma Inorganic Pyrophosphate (PPi) concentration through Week 52
기간: 52 weeks (Baseline through Week 52)
|
For each subject, plasma PPi will be measured via a series of blood samples obtained throughout the study, comparing the subject's baseline value over time. |
52 weeks (Baseline through Week 52)
|
|
Change from Baseline in skeletal abnormalities as measured by the Radiographic Global Impression of Change (RGI-C) global score through Week 52
기간: 52 weeks (Baseline through Week 52)
|
The RGI-C is an overall radiographic score which can be used to monitor response to a therapeutic intervention comparing scores from 2 time points. A determination of healing on a scale of 0 to +3 with 0 being no change or healing and +3 being complete healing; worsening is also measured on a scale of 0 to -3 with 0 being no change and -3 being severe worsening. |
52 weeks (Baseline through Week 52)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from Baseline in rickets as measured by Rickets Severity Score (RSS) total score through Week 52
기간: Baseline, Week 26, Week 52
|
The RSS assesses rickets severity by utilizing a scoring system that uses a scale from 0 to 4 for the wrists and 0 to 6 for the knees, to generate a total score of 0 to 10, where 0 is normal and 10 is the worst score possible ie, most severe skeletal abnormalities observed radiographically. |
Baseline, Week 26, Week 52
|
|
Change from Baseline in growth Z-score (height/body length and weight) through Week 52
기간: Baseline, Day 29, Week 8, Week 13, Week 26, Week 39, Week 52
|
A Z-score represents the degree to which that particular measurement for that individual differs from the reference value in the general population. (height/body length and weight) through Week 52 |
Baseline, Day 29, Week 8, Week 13, Week 26, Week 39, Week 52
|
|
Area under the Plasma Concentration versus Time Curve (AUC) of INZ-701
기간: 52 weeks (Randomized Treatment Period)
|
For each subject, variation of concentration of INZ-701 in the plasma will be measured via a series of blood samples obtained throughout the study, comparing the subject's baseline value over time. |
52 weeks (Randomized Treatment Period)
|
|
Maximum Plasma Concentration (Cmax) of INZ-701
기간: 52 weeks (Randomized Treatment Period)
|
For each subject, the maximum concentration of INZ-701 in the plasma will be measured via a series of blood samples obtained throughout the study, comparing the subject's baseline value over time. |
52 weeks (Randomized Treatment Period)
|
|
Change from Baseline in ENPP1 activity (µM/min) through week 52
기간: 52 weeks (Randomized Treatment Period)
|
For each subject, the activity of INZ-701 (µM/min) in the serum will be assessed through hydrolysis of a substrate to the enzyme, via a series of blood samples obtained throughout the study, comparing the subject's baseline value over time. |
52 weeks (Randomized Treatment Period)
|
공동 작업자 및 조사자
협력자
협력자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- INZ701-106
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .